Fritextsökning
Artiklar per år
Innehållstyper
-
Viktor Hrvota dubblar vd-skapet – tar över Umecrine Cognition
Umecrine Cognition har utsett Viktor Drvota till ny vd efter avgående Anders Karlsson.
-
An organ seldom in the spotlight – but utterly vital
The kidneys consist of more than 40 types of cells and have more functions in the body than most people know. Julie Williams leads AstraZeneca’s work in preclinical research about kidney diseases. “They are probably one of the most complicated organs in the body, and I like a challenge”, she says.
-
Årets cancerforskare har fokus på tumörens närmiljö
Kristian Pietras, professor i molekylär medicin vid Lunds universitet, har utsetts till Årets cancerforskare för sin forskning kring tumörens mikromiljö.
-
Investment CEO: “The Nordics are outstanding in creating successful medtech companies”
Since the beginning of last month, Susanna Francke Rodau has been a partner and the new CEO of Segulah Medical Acceleration, which invests in medical technology. In an interview she tells about which companies the investment company prefers to invest in, which companies she believes in the most in the portfolio and why she accepted the new position.
-
Elekta föll efter rapport – men har fulla orderböcker
En lägre vinst än väntat fick strålbehandlingsbolaget Elekta att backa rejält på börsen. Samtidigt presenterades en stor order i Mexiko och ett nytt USA-samarbete.
-
Björn Arvidsson will lead research and innovation in Region Uppsala
The Swedish life science profile Björn Arvidsson has been appointed Director of Research and Innovation for Region Uppsala.
-
Link expanderar i Finland – ”Ett betydande tillskott”
Kontraktsforskningsbolaget Link Medical expanderar genom att förvärva finländska branschkollegan CRST Oy.
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks approved treatment alternatives. "We can't do that on our own – our entire R&D activities are about working together with others," says the company's CEO Jens Lindberg.
-
Medivir planerar ny stor studie: ”Handlar om att jobba tillsammans med andra”
Medivir är ett litet bolag med en stor uppgift: att ta sin läkemedelskandidat, via omfattande kliniska studier, hela vägen till en patientgrupp som idag saknar godkända behandlingsalternativ. ”Det kan vi inte göra på egen hand – hela vår utvecklingsverksamhet handlar om att jobba tillsammans med andra”, säger företagets vd Jens Lindberg.
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the billion-selling GLP1 analogues. ‘‘Basically, I expect all the beneficial effects that they have, but not the same side effect profile,’’ company founder Dorte X Gram said in an interview with Life Science Sweden.
-
This years Nobel prize in medicine – “Changed the understanding of how genes are controlled”
This year’s Nobel Prize in Physiology or Medicine goes to the discovery that small RNA molecules, known as microRNAs, control how genes are regulated. Understanding the mechanism has changed our view of human biology and evolution, says KI Professor András Simon.
-
An increasing number of people are falling ill with TBE – “Much more research is needed”
Tick-borne meningitis, or TBE, is an increasingly common disease in Sweden. Currently, there is a vaccine against the disease but no drugs. Researcher Anna Överby Wernstedt is studying the processes that occur in the brain during a TBE infection and hopes to contribute to developing a treatment.
-
Obesity-drug pioneers win Lasker Award
This year’s Lasker Prize in Clinical Research has been awarded to three researchers for their discoveries in GLP-1-based drugs that, according to the jury, “have revolutionised the treatment of obesity”. Among others, Novo Nordisk’s Lotte Bjerre Knudsen is honoured.
-
Xvivo förvärvar plattform för smidigare transplantationsprocess – ”Tar bort onödiga hinder”
Göteborgsbaserade Xvivo Perfusion förvärvar ett digitalt verktyg för kommunikation och arbetsflöde vid transplantationsprocesser från amerikanska Omnilife.
-
“We should avoid surgery if we can”
Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about role models, surgery and Sweden’s strengths and weaknesses in medical research.
-
Abbvie flyttar in i Forskaren
Elekta, Astra Zeneca och ett tiotal andra life science-bolag är redan på plats. Nu flyttar även läkemedelsbolaget Abbvie sitt Sverigekontor till Forskaren i Hagastaden.
-
Getinge köper amerikanskt bolag – ska ”omdefiniera marknadsstandarden”
Getinge har ingått ett avtal om att förvärva det amerikanska företaget Paragonix Technologies. Köpet ska positionera Getinge inom transplantationsområdet.
-
Scandinavian CRO köps av finländskt bolag – ”Utmärkta möjligheter att växa”
Kontraktsforskningsbolaget Scandinavian CRO förvärvas av Helsingforsbaserade Labquality.
-
The investor: “The major common diseases are hot again”
She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of the industry with Nina Rawal from Trill Impact Advisory.
-
Investeraren: ”De stora folksjukdomarna är heta igen”
Hon har tidigare utsetts till Årets investerare och ska nu moderera kongressen The Future of Swedish & Danish Life Science. Vi tar tempen på branschen med Nina Rawal från Trill Impact Advisory.
-
CTR förvärvar Lundabolag inom topikala läkemedel
Bolagsgruppen Center for Translational Research, CTR, utökar sin portfölj genom förvärv av kontraktsforskningsbolaget Zelmic.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial for maintaining normal haemostasis.
-
Olinkgrundare kan få tungt europeiskt uppfinnarpris
Två av forskarna bakom Olinks succé, Ulf Landegren och Simon Fredriksson, har utsetts till finalister i European Inventor Award 2024 för sina upptäckter inom storskalig proteinanalys.
-
Forskaren in Hagastaden now inagurated
The real estate company Vectura's life science center in Hagastaden, Forskaren, is now inaugurated. The opening was attended by people from the industry, politicians and royalty.
BREAKING